Kezar Life Sciences (KZR) Competitors $4.31 -0.16 (-3.58%) Closing price 04:00 PM EasternExtended Trading$4.31 0.00 (0.00%) As of 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KZR vs. GNLX, MCRB, PLX, SKYE, ONCY, FTLF, TARA, HURA, BHST, and ACTUShould you be buying Kezar Life Sciences stock or one of its competitors? The main competitors of Kezar Life Sciences include Genelux (GNLX), Seres Therapeutics (MCRB), Protalix BioTherapeutics (PLX), Skye Bioscience (SKYE), Oncolytics Biotech (ONCY), FitLife Brands (FTLF), Protara Therapeutics (TARA), TuHURA Biosciences (HURA), BioHarvest Sciences (BHST), and Actuate Therapeutics (ACTU). These companies are all part of the "pharmaceutical products" industry. Kezar Life Sciences vs. Its Competitors Genelux Seres Therapeutics Protalix BioTherapeutics Skye Bioscience Oncolytics Biotech FitLife Brands Protara Therapeutics TuHURA Biosciences BioHarvest Sciences Actuate Therapeutics Genelux (NASDAQ:GNLX) and Kezar Life Sciences (NASDAQ:KZR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, profitability, earnings, analyst recommendations, institutional ownership, valuation and media sentiment. Is GNLX or KZR more profitable? Kezar Life Sciences' return on equity of -61.15% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -93.04% -74.17% Kezar Life Sciences N/A -61.15%-50.27% Do institutionals and insiders hold more shares of GNLX or KZR? 37.3% of Genelux shares are owned by institutional investors. Comparatively, 67.9% of Kezar Life Sciences shares are owned by institutional investors. 9.3% of Genelux shares are owned by insiders. Comparatively, 10.4% of Kezar Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has higher valuation and earnings, GNLX or KZR? Genelux has higher earnings, but lower revenue than Kezar Life Sciences. Genelux is trading at a lower price-to-earnings ratio than Kezar Life Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$10K12,611.84-$29.87M-$0.88-3.80Kezar Life Sciences$7M4.50-$83.74M-$10.82-0.40 Which has more risk & volatility, GNLX or KZR? Genelux has a beta of -0.34, meaning that its stock price is 134% less volatile than the S&P 500. Comparatively, Kezar Life Sciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Do analysts recommend GNLX or KZR? Genelux presently has a consensus target price of $17.75, suggesting a potential upside of 431.44%. Kezar Life Sciences has a consensus target price of $39.50, suggesting a potential upside of 816.47%. Given Kezar Life Sciences' higher probable upside, analysts clearly believe Kezar Life Sciences is more favorable than Genelux.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Kezar Life Sciences 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33 Does the media favor GNLX or KZR? In the previous week, Genelux and Genelux both had 2 articles in the media. Genelux's average media sentiment score of 0.94 beat Kezar Life Sciences' score of 0.93 indicating that Genelux is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genelux 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kezar Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryKezar Life Sciences beats Genelux on 8 of the 15 factors compared between the two stocks. Get Kezar Life Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for KZR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KZR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KZR vs. The Competition Export to ExcelMetricKezar Life SciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$32.66M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-0.4021.0428.0720.05Price / Sales4.50284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book0.278.378.665.87Net Income-$83.74M-$55.19M$3.25B$258.55M7 Day Performance-0.92%5.89%4.20%2.23%1 Month Performance5.38%17.63%10.82%12.76%1 Year Performance-34.53%5.09%34.70%19.36% Kezar Life Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KZRKezar Life Sciences4.1969 of 5 stars$4.31-3.6%$39.50+816.5%-32.4%$32.66M$7M-0.4060GNLXGenelux1.2316 of 5 stars$3.51+5.4%$17.75+405.7%+59.9%$125.74M$10K-3.9910Positive NewsAnalyst ForecastGap UpMCRBSeres Therapeutics3.5046 of 5 stars$13.85-1.6%$73.67+431.9%-48.1%$122.86M$126.32M-3.01330Positive NewsPLXProtalix BioTherapeutics2.9429 of 5 stars$1.52+4.8%$15.00+886.8%+34.2%$121.00M$59.76M-11.69200Gap UpSKYESkye Bioscience2.5339 of 5 stars$3.73-4.1%$16.60+345.0%-32.7%$120.49MN/A-4.5511News CoverageGap UpONCYOncolytics Biotech1.6669 of 5 stars$1.21-4.7%$4.33+258.1%+10.7%$119.74MN/A-4.1730News CoverageUpcoming EarningsFTLFFitLife Brands4.0845 of 5 stars$12.97+1.8%$20.50+58.1%-20.0%$119.64M$64.47M15.4420News CoveragePositive NewsGap DownTARAProtara Therapeutics2.1431 of 5 stars$3.42+11.0%$20.50+499.4%+44.0%$118.83MN/A-1.9930HURATuHURA Biosciences1.7927 of 5 stars$2.55-2.7%$12.67+396.7%N/A$114.44MN/A0.00N/ABHSTBioHarvest SciencesN/A$6.84-1.2%$13.67+99.8%N/A$113.66M$25.19M-13.68N/ANews CoverageACTUActuate Therapeutics2.3621 of 5 stars$5.66-1.7%$20.50+262.2%N/A$113.01MN/A0.0010News Coverage Related Companies and Tools Related Companies GNLX Competitors MCRB Competitors PLX Competitors SKYE Competitors ONCY Competitors FTLF Competitors TARA Competitors HURA Competitors BHST Competitors ACTU Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KZR) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kezar Life Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kezar Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
